Israel - English - Ministry of Health

dexcel ltd, israel - metformin hydrochloride - caplets - metformin hydrochloride 850 mg - metformin - metformin - treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.• in adults, glucomin may be used as monotherapy or in combination with other oral anti-diabetic agents or with insulin.• in children from 10 years of age and adolescents, glucomin may be used as monotherapy or in combination with insulin.a reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet failure.

Israel - English - Ministry of Health

dexcel ltd, israel - captopril - tablets - captopril 25 mg - captopril - captopril - -hypertensioncongestive heart failure-insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.-improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less or equals to 40% and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.

Israel - English - Ministry of Health

dexcel ltd, israel - captopril - tablets - captopril 50 mg - captopril - captopril - -hypertensioncongestive heart failure-insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.-improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less or equals to 40% and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - olanzapine 5 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - olanzapine 7.5 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - olanzapine 10 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder : the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - olanzapine 15 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - olanzapine 20 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - English - Ministry of Health

dexcel ltd, israel - captopril - tablets - captopril 12.5 mg - captopril - ace inhibitors, plain - -hypertensioncongestive heart failure-insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.-improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less or equals to 40% and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

kotra pharma (m) sdn. bhd. - etoricoxib -